|
1.
|
|
13 p, 7.0 MB |
Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning
/
Mueller, Yvonne M. (Erasmus University Medical Center) ;
Schrama, Thijs J. (Erasmus University Medical Center) ;
Ruijten, Rik (Erasmus University Medical Center) ;
Schreurs, Marco W. J. (Erasmus University Medical Center) ;
Grashof, Dwin G. B. (Erasmus University Medical Center) ;
van de Werken, Harmen J. G. (Erasmus University Medical Center) ;
Lasinio, Giovanna Jona (University of Rome "La Sapienza") ;
Álvarez-Sierra, Daniel (Hospital Universitari Vall d'Hebron) ;
Kiernan, Caoimhe H. (Erasmus University Medical Center) ;
Castro Eiro, Melisa D. (Erasmus University Medical Center) ;
van Meurs, Marjan (Erasmus University Medical Center) ;
Brouwers-Haspels, Inge (Erasmus University Medical Center) ;
Zhao, Manzhi (Erasmus University Medical Center) ;
Li, Ling (Erasmus University Medical Center) ;
de Wit, Harm (Erasmus University Medical Center) ;
Ouzounis, Christos A. (Chemical Process & Energy Resources Institute, Centre for Research & Technology Hellas, Thermi) ;
Wilmsen, Merel E. P. (Erasmus University Medical Center) ;
Alofs, Tessa M. (Erasmus University Medical Center) ;
Laport, Danique A. (Erasmus University Medical Center) ;
van Wees, Tamara (Erasmus University Medical Center) ;
Kraker, Geoffrey (Cytek Biosciences, Fremont, CA USA) ;
Jaimes, Maria C. (Cytek Biosciences, Fremont, CA USA) ;
Van Bockstael, Sebastiaan (Cytek Biosciences, Fremont, CA USA) ;
Hernández-González, Manuel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Rokx, Casper (Erasmus University Medical Center) ;
Rijnders, Bart J. A. (Erasmus University Medical Center) ;
Pujol-Borrell, Ricardo (Vall d'Hebron Institut d'Oncologia) ;
Katsikis, Peter D. (Erasmus University Medical Center) ;
Universitat Autònoma de Barcelona
Quantitative or qualitative differences in immunity may drive clinical severity in COVID-19. Although longitudinal studies to record the course of immunological changes are ample, they do not necessarily predict clinical progression at the time of hospital admission. [...]
2022 -  10.1038/s41467-022-28621-0
Nature communications, Vol. 13 (february 2022)
|
|
|
6.
|
|
11 p, 779.0 KB |
Antitubercular drugs for an old target : GSK693 as a promising InhA direct inhibitor
/
Martínez-Hoyos, María (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Perez-Herran, Esther (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Gulten, Gulcin (Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA) ;
Encinas, Lourdes (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Álvarez-Gómez, Daniel (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Alvarez, Emilio (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Ferrer-Bazaga, Santiago (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
García-Pérez, Adolfo (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Ortega, Fátima (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Angulo-Barturen, Iñigo (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Rullas-Trincado, Joaquin (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Blanco Ruano, Delia (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Torres, Pedro (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Castañeda, Pablo (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Huss, Sophie (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Fernández Menéndez, Raquel (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
González del Valle, Silvia (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Ballell, Lluis (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Barros, David (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Modha, Sundip (Target and Pathway Validation, Molecular Discovery Research, GlaxoSmithKline, Stevenage, Herts, UK) ;
Dhar, Neeraj (School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne 1015, Switzerland) ;
Signorino-Gelo, François (Target and Pathway Validation, Molecular Discovery Research, GlaxoSmithKline, Stevenage, Herts, UK) ;
McKinney, John D. (Target and Pathway Validation, Molecular Discovery Research, GlaxoSmithKline, Stevenage, Herts, UK) ;
García-Bustos, Jose Francisco (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Lavandera, Jose Luis (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Sacchettini, James C. (Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA) ;
Jimenez, M. Soledad (Instituto de Salud Carlos III) ;
Martín-Casabona, Nuria (Hospital Universitari Vall d'Hebron) ;
Castro-Pichel, Julia (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Mendoza-Losana, Alfonso (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Universitat Autònoma de Barcelona
Despite being one of the first antitubercular agents identified, isoniazid (INH) is still the most prescribed drug for prophylaxis and tuberculosis (TB) treatment and, together with rifampicin, the pillars of current chemotherapy. [...]
2016 - 10.1016/j.ebiom.2016.05.006
EBioMedicine, Vol. 8 (may 2016) , p. 291-301
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
